Form 4: Outlook Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Kevin Michael Lundquist, Chief Financial Officer of Outlook Therapeutics, Inc., received 500,000 shares of common stock on September 1, 2026.
Summary
- Grant/award: acquired 500,000 Employee Stock Option (Right to Buy) on September 1, 2026; holds 500,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kevin Michael Lundquist — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Grant/award | Employee Stock Option (Right to Buy) | 500,000 | — | — | 500,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Grant/award (500,000 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., neutral, Kevin Michael Lundquist
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.